Literature DB >> 22740197

Metabolic syndrome and breast cancer: an overview.

G Gezgen1, E C Roach, M C Kizilarslanoglu, I Petekkaya, K Altundag.   

Abstract

Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women and the most important cause of cancer-related deaths among women. This disease is on the rise in Turkey. Metabolic syndrome is a cluster of metabolic disturbances including insulin resistance, dyslipidemia, hypertension, abdominal obesity and high blood sugar. Several studies have examined the association of the individual components of the metabolic syndrome with breast cancer. More recent studies have shown it to be an independent risk factor for breast cancer. It has also been associated with poorer prognosis, increased incidence, a more aggressive tumor phenotype. Basic research studies are now in progress to illuminate the molecular pathways and mechanisms that are behind this correlation. Given the fact that all of the components of metabolic syndrome are modifiable risk factors, preventive measures must be established to improve the outcome of breast cancer patients. In this review we set the background by taking into account previous studies which have identified the components of metabolic syndrome individually as breast cancer risk factors. Then we present the latest findings which elaborate possible explanations regarding how metabolic syndrome as a single entity may affect breast cancer risk.

Entities:  

Mesh:

Year:  2012        PMID: 22740197

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  9 in total

1.  High glucose and insulin enhance uPA expression, ROS formation and invasiveness in breast cancer-derived cells.

Authors:  Luis Antonio Flores-López; María Guadalupe Martínez-Hernández; Rubí Viedma-Rodríguez; Margarita Díaz-Flores; Luis Arturo Baiza-Gutman
Journal:  Cell Oncol (Dordr)       Date:  2016-04-22       Impact factor: 6.730

2.  Energy intake correlates with the levels of fatty acid synthase and insulin-like growth factor-1 in male and female C57BL/6 mice.

Authors:  Anup S Ramdhave; Shreesh Ojha; Mukesh Nandave
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

3.  Metabolic syndrome and outcome after breast reconstruction.

Authors:  Areerat Ounhasuttiyanon; Visnu Lohsiriwat
Journal:  Gland Surg       Date:  2014-02

4.  Associations of metabolic syndrome and C-reactive protein with mortality from total cancer, obesity-linked cancers and breast cancer among women in NHANES III.

Authors:  Wambui G Gathirua-Mwangi; Yiqing Song; Patrick O Monahan; Victoria L Champion; Terrell W Zollinger
Journal:  Int J Cancer       Date:  2018-03-14       Impact factor: 7.396

5.  Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship.

Authors:  Balazs I Bodai; Therese E Nakata
Journal:  Perm J       Date:  2020

6.  Targeting of PP2Cδ By a Small Molecule C23 Inhibits High Glucose-Induced Breast Cancer Progression In Vivo.

Authors:  Ke Wu; Xiaoting Yu; Zhimin Huang; Donghui Zhu; Xianghua Yi; Ying-Li Wu; Qiongyu Hao; Kevin T Kemp; Yahya Elshimali; Roshni Iyer; Kytai Truong Nguyen; Shilong Zheng; Guanglin Chen; Qiao-Hong Chen; Guangdi Wang; Jaydutt V Vadgama; Yong Wu
Journal:  Antioxid Redox Signal       Date:  2018-07-13       Impact factor: 7.468

7.  Insights from engraftable immunodeficient mouse models of hyperinsulinaemia.

Authors:  Michelle L Maugham; Patrick B Thomas; Gabrielle J Crisp; Lisa K Philp; Esha T Shah; Adrian C Herington; Chen Chen; Laura S Gregory; Colleen C Nelson; Inge Seim; Penny L Jeffery; Lisa K Chopin
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

8.  Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer.

Authors:  R S Wahdan-Alaswad; S M Edgerton; H S Salem; A D Thor
Journal:  J Oncol Transl Res       Date:  2018-03-21

9.  Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization.

Authors:  Ji-Young Jang; Jong-Kuen Lee; Yoon-Kyung Jeon; Chul-Woo Kim
Journal:  BMC Cancer       Date:  2013-09-17       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.